- AMPA (GluR1 & R2) (1)
- AMPA (GluR1 & R2)
- DPPX (1)
- DPPX
- GABA B (1)
- GABA B
- NMDA (1)
- NMDA
- VGKC (LGI1, CASPR2) (1)
- VGKC (LGI1, CASPR2)
Autoimmune encephalitis is a condition characterized by inflammation in the brain due to an immune response against the brain’s own tissues. To diagnose autoimmune encephalitis and identify specific autoantibodies associated with the condition, an Autoimmune Encephalitis Panel is performed. The panel typically includes tests for various autoantibodies, and in this case, the panel includes tests for AMPA (GluR1 & R2), DPPX, GABA B, NMDA, and VGKC (LGI1, CASPR2).
The tests included in the Autoimmune Encephalitis Panel-2 are as follows:
- AMPA (GluR1 & R2) – To detect autoantibodies against AMPA receptors in the brain.
- DPPX – To detect autoantibodies against the Dipeptidyl-peptidase-like protein 6 (DPPX) receptor.
- GABA B – To detect autoantibodies against the GABA B receptor.
- NMDA – To detect autoantibodies against the N-methyl-D-aspartate (NMDA) receptor.
- VGKC (LGI1, CASPR2) – To detect autoantibodies against voltage-gated potassium channel (VGKC) complex, which includes antibodies against leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein 2 (CASPR2) receptors.
The presence of these autoantibodies can help in the diagnosis and management of autoimmune encephalitis. It is important to note that the tests may vary depending on the specific laboratory and healthcare provider.